Trial Profile
A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia Patients Not Eligible for Intensive Induction Therapy
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Defosbarasertib (Primary) ; Azacitidine; Azacitidine; Venetoclax
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors AstraZeneca; AstraZeneca AB
- 24 Mar 2022 According to ClinicalTrials.gov record, protocol has been amended as treatment arm changed from 8 to 13, time frame of primary endpoint changed from 28 days to 42 months, other endpoint also changed, Study phase changes from 1/2 to phase 1
- 19 Jul 2021 Status changed from completed to discontinued.
- 27 May 2021 Status changed from active, no longer recruiting to completed.